Fluid biomarker agreement and interrelation in dementia due to Alzheimer's disease

被引:5
|
作者
Alexopoulos, Panagiotis [1 ,2 ]
Roesler, Jennifer [2 ]
Werle, Lukas [2 ,3 ]
Thierjung, Nathalie [2 ]
Lentzari, Iliana [1 ]
Ortner, Marion [2 ]
Grimmer, Timo [2 ]
Laskaris, Nikolaos [4 ]
Politis, Antonios [5 ,6 ]
Gourzis, Philippos [1 ]
Kurz, Alexander [2 ]
Perneczky, Robert [7 ,8 ,9 ,10 ]
机构
[1] Univ Patras, Dept Psychiat, Rion 26500, Greece
[2] Tech Univ Munich, Dept Psychiat & Psychotherapy, Ismaninger Str 22, D-81675 Munich, Germany
[3] Max Planck Inst Psychiat, Munich, Germany
[4] Aristotle Univ Thessaloniki, Dept Informat, Thessaloniki 54124, Greece
[5] Univ Athens, Eginit Hosp, Dept Psychiat 1, Vassilissis Sofias Ave 72-74, Athens 11528, Greece
[6] Johns Hopkins Med Sch, Div Geriatr Psychiat & Neuropsychiat, Dept Psychiat, Baltimore, MD USA
[7] Ludwig Maximilians Univ Munchen, Dept Psychiat & Psychotherapy, Nussbaumstr 7, D-80336 Munich, Germany
[8] Imperial Coll Sci Technol & Med, Sch Publ Hlth, Neuroepidemiol & Ageing Res Unit, Fac Med, London, England
[9] West London Mental Hlth NHS Trust, London, England
[10] German Ctr Neurodegenerat Dis DZNE Munich, Munich, Germany
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
beta-Amyloid; 1-42; Total tau; Phosphorylated tau 181; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; APOLIPOPROTEIN-E; CSF BIOMARKERS; AMYLOID-BETA; DIAGNOSTIC EVALUATION; TAU PATHOLOGY; RECOMMENDATIONS; DECLINE; MARKERS;
D O I
10.1007/s00702-017-1810-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The cerebrospinal fluid (CSF) levels of beta-amyloid 42, total tau, and phosphorylated tau 181 are supposed to be all continuously abnormal in dementia due to Alzheimer's disease (AD), being the most advanced disease stage. The aim of the present study, which included a monocentric and a multicentric sample (N = 119 and 178, respectively), was to investigate the degree of CSF biomarker agreement and interrelation in AD dementia. Based on previously published cut-off values, biomarker values were categorized as positive or negative for AD (dichotomization strategy) and as either positive, negative, or borderline (trichotomization strategy). The statistical analyses relied on distance correlation analysis and kappa (k) statistics. Poor agreement (k < 0.4) and low interrelations between the studied biomarkers were detected in all cases with the exception of the interrelation between the markers total tau and phosphorylated tau 181, especially in the monocentric sample. Interestingly, lower interrelation and agreement degrees were observed in carriers of the Apolipoprotein E epsilon 4 allele compared to non-carriers. The clinical phenotype currently referred to as "AD dementia" is characterized by an inhomogeneous CSF biomarker profile, possibly mirroring the complex genesis of AD-typical dementia symptoms and pointing to the necessity of shedding more light on the hypothesis of biomarker stability over time in symptomatic AD.
引用
收藏
页码:193 / 201
页数:9
相关论文
共 50 条
  • [21] Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer's Disease
    Omar, Syed Haris
    Preddy, John
    JOURNAL OF PERSONALIZED MEDICINE, 2020, 10 (03): : 1 - 20
  • [22] Fluid biomarkers for Alzheimer's disease: standardization and recent developments
    Zetterberg, Henrik
    Visser, Pieter Jelle
    BIOMARKERS IN MEDICINE, 2012, 6 (04) : 363 - 364
  • [23] The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative
    Luis Molinuevo, Jose
    Blennow, Kaj
    Dubois, Bruno
    Engelborghs, Sebastiaan
    Lewczuk, Piotr
    Perret-Liaudet, Armand
    Teunissen, Charlotte E.
    Parnetti, Lucilla
    ALZHEIMERS & DEMENTIA, 2014, 10 (06) : 808 - 817
  • [24] Longitudinal Stability of Cerebrospinal Fluid Biomarker Levels: Fulfilled Requirement for Pharmacodynamic Markers in Alzheimer's Disease
    Le Bastard, Nathalie
    Aerts, Laetitia
    Sleegers, Kristel
    Martin, Jean-Jacques
    Van Broeckhoven, Christine
    De Deyn, Peter Paul
    Engelborghs, Sebastiaan
    JOURNAL OF ALZHEIMERS DISEASE, 2013, 33 (03) : 807 - 822
  • [25] Clinical value of Alzheimer's disease biomarker testing
    Patel, Khushbu J.
    Yang, David
    Best, John R.
    Chambers, Colleen
    Lee, Philip E.
    Henri-Bhargava, Alexandre
    Funnell, Clark R.
    Foti, Dean J.
    Pettersen, Jacqueline A.
    Feldman, Howard H.
    Nygaard, Haakon B.
    Hsiung, Ging-Yuek R.
    DeMarco, Mari L.
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2024, 10 (02)
  • [26] Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia
    Rostgaard, Nina
    Waldemar, Gunhild
    Nielsen, Jorgen Erik
    Simonsen, Anja Hviid
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2015, 40 (1-2) : 54 - 62
  • [27] Inhaled Xenon Washout as a Biomarker of Alzheimer's Disease
    Hane, Francis T.
    Li, Tao
    Plata, Jennifer-Anne
    Hassan, Ayman
    Granberg, Karl
    Albert, Mitchell S.
    DIAGNOSTICS, 2018, 8 (02):
  • [28] Cerebrospinal fluid biomarkers of Alzheimer's disease
    Fagan, Anne M.
    Holtzman, David M.
    BIOMARKERS IN MEDICINE, 2010, 4 (01) : 51 - 63
  • [29] Cerebrospinal fluid biomarkers in Alzheimer's disease
    Hugon, Jacques
    Dumurgier, Julien
    Cognat, Emmanuel
    Paquet, Claire
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2018, 202 (1-2): : 307 - 318
  • [30] Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative
    Vanderstichele, Hugo
    Bibl, Mirko
    Engelborghs, Sebastiaan
    Le Bastard, Nathalie
    Lewczuk, Piotr
    Molinuevo, Jose Luis
    Parnetti, Lucilla
    Perret-Liaudet, Armand
    Shaw, Leslie M.
    Teunissen, Charlotte
    Wouters, Dirk
    Blennow, Kaj
    ALZHEIMERS & DEMENTIA, 2012, 8 (01) : 65 - 73